Literature DB >> 11504807

Antidepressant-like behavioral effects in 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) receptor mutant mice.

A J Mayorga1, A Dalvi, M E Page, S Zimov-Levinson, R Hen, I Lucki.   

Abstract

The development of serotonin receptor knockout mice has provided an opportunity to study antidepressant drug effects in animals with targeted genetic deletion of receptors involved in antidepressant responses. In the current study, the effects of two types of antidepressant drugs, the selective serotonin reuptake inhibitors fluoxetine and paroxetine and the selective norepinephrine reuptake inhibitor desipramine, were examined in 5-hydroxytryptamine (5-HT)(1A) and 5-HT(1B) receptor mutant mice using the tail suspension test (TST). Under baseline conditions, the immobility of 5-HT(1A) receptor mutant mice, but not 5-HT(1B) receptor mutant mice, was significantly lower than that of wild-type mice. The decreased baseline immobility in 5-HT(1A) receptor mutant mice was reversed by pretreatment with alpha-methyl-para-tyrosine, but not by para-chlorophenylalanine, suggesting mediation by enhanced catecholamine function. In wild-type mice, fluoxetine (10.0--20.0 mg/kg i.p.) and desipramine (5.0--20.0 mg/kg i.p.) both significantly decreased immobility in the TST. In 5-HT(1A) receptor mutant mice, desipramine (20.0 mg/kg i.p.) significantly decreased immobility, whereas fluoxetine (20.0 mg/kg i.p.) and paroxetine (20.0 mg/kg i.p.) had no effect. The immobility of 5-HT(1B) receptor mutant mice was decreased similarly by desipramine (5.0--20.0 mg/kg i.p.). However, the effect of low doses of fluoxetine were significantly augmented in the 5-HT(1B) receptor mutant mice (2.5--20.0 mg/kg i.p.) compared with wild-type mice. Administration of selective 5-HT receptor antagonists in wild-type mice partially reproduced the phenotypes of the mutant mice. These results suggest that 5-HT(1A) and 5-HT(1B) receptors have different roles in the modulation of the response to antidepressant drugs in the TST.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11504807

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  57 in total

Review 1.  Role of pharmacogenomics in individualising treatment with SSRIs.

Authors:  Dalu Mancama; Robert W Kerwin
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

2.  Cellular correlates of anxiety in CA1 hippocampal pyramidal cells of 5-HT1A receptor knockout mice.

Authors:  Emily Freeman-Daniels; Sheryl G Beck; Lynn G Kirby
Journal:  Psychopharmacology (Berl)       Date:  2010-10-28       Impact factor: 4.530

Review 3.  5-HT(1A) receptor function in major depressive disorder.

Authors:  Jonathan Savitz; Irwin Lucki; Wayne C Drevets
Journal:  Prog Neurobiol       Date:  2009-02-07       Impact factor: 11.685

4.  A Lack of Serotonin 1B Autoreceptors Results in Decreased Anxiety and Depression-Related Behaviors.

Authors:  Katherine M Nautiyal; Laurent Tritschler; Susanne E Ahmari; Denis J David; Alain M Gardier; René Hen
Journal:  Neuropsychopharmacology       Date:  2016-06-29       Impact factor: 7.853

5.  Participation of 5-HT(1B) receptors in the inhibitory actions of serotonin on masculine sexual behaviour of mice: pharmacological analysis in 5-HT(1B) receptor knockout mice.

Authors:  Gabriela Rodríguez-Manzo; Carolina López-Rubalcava; Rene Hen; Alonso Fernández-Guasti
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

6.  Altered skeletal muscle mitochondrial biogenesis but improved endurance capacity in trained OPA1-deficient mice.

Authors:  F Caffin; A Prola; J Piquereau; M Novotova; D J David; A Garnier; D Fortin; M V Alavi; V Veksler; R Ventura-Clapier; F Joubert
Journal:  J Physiol       Date:  2013-09-16       Impact factor: 5.182

Review 7.  Serotonin 1A and Serotonin 4 Receptors: Essential Mediators of the Neurogenic and Behavioral Actions of Antidepressants.

Authors:  Benjamin Adam Samuels; Indira Mendez-David; Charlène Faye; Sylvain André David; Kerri A Pierz; Alain M Gardier; René Hen; Denis J David
Journal:  Neuroscientist       Date:  2014-12-08       Impact factor: 7.519

8.  Differential effects of acute and repeated citalopram in mouse models of anxiety and depression.

Authors:  Cedric Mombereau; Tamar L Gur; Jennifer Onksen; Julie A Blendy
Journal:  Int J Neuropsychopharmacol       Date:  2009-12-14       Impact factor: 5.176

Review 9.  Treatment-resistant depression: are animal models of depression fit for purpose?

Authors:  Paul Willner; Catherine Belzung
Journal:  Psychopharmacology (Berl)       Date:  2015-08-21       Impact factor: 4.530

10.  Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes.

Authors:  Mark J Millan; Sylvie Veiga; Sylvie Girardon; Mauricette Brocco
Journal:  Psychopharmacology (Berl)       Date:  2003-04-30       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.